Atrial fibrillation (AF) is the most commonly sustained arrhythmia and it is the most heterogeneous arrhythmia with regard to the individual spectrum of resulting symptoms. Assessment of quality of life has received increasing attention as an outcome measure of the subjective sequelae of the disease. At present, conclusive data concerning the prognostic benefits of any therapeutic intervention are lacking, with the exception of the proven need for antithrombotic treatment. Therefore, assessment of any benefit from treatment in the management of patients with AF depends on documentation of symptomatic improvement. Exercise tolerance, duration of sinus rhythm after cardioversion and number of relapses with paroxysmal AF, for example, have been used as study end-points for evaluating different therapeutic modalities. Although these factors -as assessed in controlled studiesreflect some effect of treatment, these surrogate end-points were often not accompanied by appropriate measurements of the subjective improvement in patients' symptoms. Health-related quality of life is a summarized outcome assessment that is designed to reflect the subjective impairment in general well being caused by individual aspects of pain, and psychological, emotional and physical disturbances. In addition, measures of quality of life take into consideration the potential burdens and side effects of any treatment that leads to improvement in specific symptoms but that may negatively affect general well being. This paper reviews currently available data on the assessment of quality of life in patients with AF. Furthermore, the definition and usefulness of different clinical patterns and classifications of AF with regard to quality of life are discussed. Finally, tools and definitions for further clinical research are suggested.
will target the underlying condition. Finally, AF may occur in patients without any of the aforementioned conditions -a condition that is generally referred to as 'lone AF'. This important clinical distinction may lead to an initial categorization of AF into three subgroups (Fig. 1 ). In addition, there are numerous popular descriptions of 'typical clinical patterns' that coexist or are commonly associated with the onset of AF. Their delineation mostly stems from close clinical observation in an attempt to discriminate subtypes of the arrhythmia and to guide the initial therapeutic approach in selected patients. As summarized in Table 1 , the nomenclature of these clinical patterns is neither complete nor mutually exclusive. Therefore, apart from the presence of structural heart disease, the delineation of a specific clinical pattern in patients with AF may primarily be useful to describe coexisting conditions rather than to serve as a general classification.
Electrocardiographic features of atrial fibrillation
It was recognized early on that fibrillation waves in the 12-lead surface ECG exhibit variable characteristics. The description of irregular but partially organized fibrillation led to the classification of types I-IV AF. 1 However, a transition between fine and coarse fibrillation and the entities of (atypical and even typical) atrial flutter is frequently observed in a single patient. 2 In a recent study of pacemaker stored electrograms, 3 an atrial bipolar electrogram showed regular flutter resembling excitation in the majority of patients in whom only AF had previously been documented. In that study, these episodes were terminated by overdrive pacing in 62% of the episodes. In selected patients, the coadministration of antiarrhythmic drugs may result in more stable atrial re-entry circuits, which can be treated by radiofrequency ablation therapy. The occurrence of typical 'P on T' extrasystoles on the surface or 24-Holter electrogram has been associated with ectopic foci within the pulmonary veins, which frequently give rise to paroxysmal AF. 4 H26 G.C. Grönefeld, S.H. Hohnloser 
Temporal patterns of atrial fibrillation
In some patients AF may be self-limiting and remain a single event. In others, the arrhythmia may frequently recur after conversion to sinus rhythm or persist for a longer period of time. In contrast to the above-mentioned clinical patterns, time patterns of the onset of AF are more distinctive and better applicable to general classification. Two forms of AF are classically known: paroxysmal and continuous AF. 5 Studies investigating the potential risk for embolic complications, however, have highlighted the clinical difficulty in attributing either of these types of AF to a specific patient during a longer observation period. 6 Levy and coworkers 7 developed a method to characterize different subsets of AF from an observational study of 756 consecutive outpatients in France. In addition to paroxysmal and chronic AF, they defined a third group of patients with recent onset AF lasting between 7 and 30 days. In that study, all three subtypes had similar prognostic implications. The most pertinent discrimination for the purpose of a generally applicable classification was introduced by Sopher and Camm in 1996. 8 According to their proposal, any AF episode with a duration under 48 h should be classified as 'acute AF', whereas a repeated or ongoing arrhythmia is classified as 'chronic AF'. This 48 h time margin for acute AF is supported by evidence that recent onset AF has a high probability of spontaneous cardioversion (CV), which rapidly declines over time. 9, 10 Furthermore, anticoagulation is required for patients with AF episodes exceeding 24-48 h. 9 Therefore, stratifying patients according to their need for antithrombotic therapy or pure antiarrhythmic intervention is possible within these categories. The chronic form of AF, according to this classification, 11 is further subdivided into 'paroxysmal', 'persistent', or 'permanent AF'. Whereas paroxysmal AF repetitively terminates and recurs spontaneously, persistent AF must be converted to sinus rhythm by means of pharmacological or electrical CV. Permanent AF, by definition, is not convertible. Hence, control of ventricular rate together with anticoagulation is the remaining therapeutic strategy for patients with this type of AF. Since its introduction, this classification has raised some criticism. 12 The distinction between persistent and permanent AF includes some subjective bias because the permanent form refers to the physician's judgement that attempts at CV are futile and therefore not indicated. Similarly, patients may move from one form to another because of the progressive nature of their disease. 13 The number of attacks, and the duration and intervals between attacks in paroxysmal AF, for example, are highly variable. Further subclassifications of paroxysmal AF have been suggested by others, 14 but these considerations have not found widespread acceptance. 15 Hence, for the purpose of the initial therapeutic decision as well as for the design of epidemiological or interventional studies, the clinically based classification, in accordance with the suggestions of Sopher, Gallagher and Camm, 8, 11 remains the most useful to date.
Rationale for use of symptoms and quality of life as end-points in studies of atrial fibrillation
There is increasing awareness that AF is not a benign condition because the prognostic implications of the arrhythmia with respect to mortality and morbidity have been convincingly demonstrated. 16, 17 However, data showing benefits to mortality from therapeutic interventions, with the exception of anticoagulation therapy, 18 are lacking. A variety of surrogate endpoints (such as echocardiographic measurements, number of AF attacks on 24 h ECG recordings, time to first AF recurrence after CV and changes in exercise capacity) have been applied in studies evaluating the effects of various treatment modalities. In most of these studies, however, these surrogate end-points were not accompanied by appropriate measurements of the subjective improvement in symptoms or quality of life in afflicted patients. Improvement in symptoms, however, is not only the mainstay in everyday clinical practice but also it is increasingly recognized as an important end-point in prospective AF trials.
Assessment of symptomatic patterns in atrial fibrillation
Despite a common final pathophysiological pathway (loss of atrial contribution to cardiac output in the presence of highly disorganized atrial electrical activity), individual symptoms show a much broader variation than with many other cardiac disorders. Patients may remain completely asymptomatic during AF attacks or may suffer from a wide range of disabling symptoms. AF may be associated with palpitations, dyspnoea, dizziness, diaphoresis, general fatigue, chest discomfort, mental disturbance, exercise intolerance, or acute or chronic heart failure. In a study of consecutive patients admitted to a general hospital, 19 dyspnoea (52%), chest pain (34%), palpitations (26%) and dizziness or syncope (16%) were the most commonly reported symptoms. In the abovementioned French study, 7 palpitations were the most frequent complaint in paroxysmal AF (79% of the patients), whereas dyspnoea was reported by 58% of the patients with chronic AF. It is interesting to note that any concomitant or underlying heart disease is not necessarily predictive of the subjective impairment associated with the new onset of AF. Recently, there is increasingly more awareness that a significant number of episodes of paroxysmal AF may occur completely unrecognized by the patient. For example, in the Prevention of Atrial Fibrillation After Cardioversion trial, which was conducted in 848 patients after CV, 85% of the recurrent AF episodes were completely asymptomatic during antiarrhythmic drug treatment and were only detected by routine daily ECG trans-telephonic monitoring (data presented at the North American Society of Pacing and Electrophysiology Conference hotline session, Boston, Massachusetts, May 2001).
In attempts to cope with the broad symptomatic variation in AF, disease-specific symptom checklists or scores have been designed. Bubien and coworkers 20 were the first to introduce a symptom list for the evaluation of supraventricular tachycardia, which has subsequently been applied in studies of AF. [21] [22] [23] The University of Toronto AF Severity Scale contains 13 symptomatic items in combination with a semiquantitative grading score. 24 To reduce the statistical testing associated with multiple possibilities of bidirectional symptomatic changes, a hierarchical scale of symptom improvement was used by the German Multicentre Pharmacological Intervention in Atrial Fibrillation (PIAF) trial. 25 The primary end-point was assessed at each follow-up visit by the change compared with baseline in the three most commonly reported symptoms (palpitations, dyspnoea and dizziness) to compare a rate control with a rhythm control strategy in patients with persistent AF.
Quality of life
'Health-related quality of life' is a multidimensional construct that was introduced to validate and compare general well being in a healthy population and its limitation by different disease entities. 26 In contrast to a listing and grading of symptoms, scales for different measurements of mental, emotional and physical well being are derived from structured psychosocial questionnaires. Since their introduction approximately 30 years ago, summarized results have led to standardized assessments of health-related quality of life. 26 In diseases such as AF with various and rather unspecific symptoms, quality of life may be even more relevant because side effects and subjective burdens of a symptomatically successful therapy are inherently evaluated.
Methodology of 'quality of life' assessment
There are numerous instruments for assessing health-related quality of life. An internet search performed in July 2001 listed 800 'quality of life' questionnaires and scores designed for a broad range of health disturbances (http://www.quolid. org). As a result, studies reporting on quality of life in patients with AF rarely apply similar scores or instruments. Systematically validated methods in the evaluation of quality of life in the setting of AF are lacking. Therefore, the methods that have been applied appear to be selected predominantly according to local availability or investigator experience with the respective measurement ( Table 2) . [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Some newer studies have uniformly applied the 'Medical Outcomes Study Short Form Health Survey' (SF-36) questionaire. 38, 39 This instrument allows for comparison with other studies because of ample availability of data from patients with cardiac health impairment such as congestive heart failure, hypertension, or recent myocardial infarction. 40 However, because of the lack of assessment of AF-specific symptoms, quality of life assessment is commonly used in combination with additional symptom checklists.
Data on quality of life according to therapeutic intervention
The majority of data on quality of life in patients with AF originate from clinical studies investigating specific therapeutic interventions (Table 3 ). In one of the first observational studies, 12 patients with paroxysmal AF exhibited a significant increase on the physical dimension score of the McMaster Health Index Questionnaire and the Psychological General Well-Being Index at 6 weeks after atrioventricular (AV) node radiofrequency ablation therapy. 28 Since then, the effects of AV node ablation and pacemaker implantation on quality of life in patients with paroxysmal and persistent AF have increasingly been reported, most probably because of the invasive character of this therapeutic approach. Most of the studies found a significant reduction in quality of life prior to the intervention when data were compared with those derived from patients in sinus rhythm. 23, 32, 35 In a recent meta-analysis of 21 such studies comprising 1181 patients, 41 an improvement in quality of life was found in 87% of the patients (95% confidence interval 78-95%), with a mean increase of 25 ± 2% (95% confidence interval 21-28%) on the measured scales after ablation therapy.
In the first prospectively randomized trial of AV node ablation vs pharmacological therapy in patients with severely symptomatic paroxysmal AF, 29 improvement in quality of life (according to the Living with Heart Failure Questionnaire) and symptomatic status were significantly higher in patients assigned to ablation therapy. However, using a similar design in patients with heart failure and persistent AF, the improvement with ablation (26% of patients) was not significantly different from that observed with drug therapy (16% of patients). 30 In the German multicentre PIAF trial, 252 patients were prospectively randomized to receive rate or rhythm control. 25 Patients were followed for 12 months. Baseline assessment of quality of life by means of the SF-36 revealed a similar degree of impairment in both treatment groups.
During the study, symptomatic improvement did not differ significantly between the treatment groups. With regard to quality of life, patients showed a significant improvement in five out of eight scales of the SF-36, again with no significant differences between the two treatment Quality of life in atrial fibrillation H29 Data for age and left ventricular ejection fraction (LVEF) are mean ± standard deviation or mean (range). Structural HD indicates the percentage of study population with structural heart disease. AF=atrial fibrillation; Aflt=atrial flutter; AVNA=atrioventricular nodal ablation; CHF=congestive heart failure; chron=persistent or permanent AF; par=paroxysmal AF; SVT=supraventricular tachycardia; VT=ventricular tachycardia; VVI=ventricular pacemaker.
groups. 25 A similar improvement was found in a study in which the same assessment instrument was used in patients undergoing the Maze operation for primary rhythm treatment. 32 In that study, conducted by Lönnerholm et al., 48 patients with paroxysmal or permanent AF showed an improvement in seven out of eight of the subscales of the SF-36, with no significant difference observed between patients suffering from paroxysmal AF and those with permanent AF. 32 
Data on quality of life according to clinical presentation
Systematic evaluation of quality of life in different subgroups of patients with various clinical patterns of AF remains limited (Table 4) . This may predominantly be the result of methodological problems such as heterogeneous nomenclature of the clinical patterns of AF or the non-standardized use of different instruments to assess quality of life. For example, the studies frequently included patients with and without structural heart disease or patients with paroxysmal versus permanent AF (Table 3 and 4) . Two ongoing studies are addressing quality of life in a prospective manner and will allow for analysis of well defined patient subgroups. The International Study of Quality of Life in AF was designed as a multicentre trial comparing a series of six quality of life instruments, including SF-36, combined with clinical assessments of the type of arrhythmia, aetiology of AF, concomitant drug use, left ventricular ejection fraction, New York Heart Association functional class and left atrial size. 42 In a first report on 152 relatively young patients with paroxysmal AF, 24 quality of life was markedly impaired and was similar on most scales to previously reported health impairments in patients with heart failure or postinfarction populations. Similarly, it was noted that the extent of subjective impairment in quality of life is poorly related to traditional objective measures of illness severity, such as frequency or duration of AF, or cardiac dysfunction and functional class. 24 The North American Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) includes quality of life assessment according to the SF-36 in patients with paroxysmal and permanent AF. 43 A total of 4060 patients have been enrolled and 710 of these completed a tiered quality of life assessment at baseline. Preliminary results showed a reduction in health perception, with a mean symptom frequency score of 19.69 (maximum possible = 50) and SF-36 mean subscales ranging from 36.3 (role limitation, physical) to 73.46 (mental health). It is of interest that this study also showed a difference by sex and age, with women and patients older than 65 years reporting lower SF-36 scores and total quality of life index scores. 44 This aspect has previously been described by the investigators of the Canadian Trial of Atrial Fibrillation. 31 In their report on 170 patients with AF suffering from no or only moderate heart failure, the SF-36 at baseline showed significantly lower quality of life scores for women than for men. This difference persisted even after correcting for some differences in clinical baseline characteristics. 31 Sex and age differences with standard instruments of quality of life assessment therefore deserve prospective evaluation in further clinical studies. G.C. Grönefeld, S.H. Hohnloser 40 Second, quality of life assessment is an instrument with a low sensitivity for subtle changes. It may take some time before symptomatic improvement translates into a perceived increase in overall quality of life. In addition, because of the metric gradations of the SF-36 scales, floor or ceiling effects may occur, thereby masking therapeutically meaningful alterations in quality of life. 26, 45 Third, the results of multiple, different quality of life scales may not be simply summarized. Therefore, a transfer of observed changes in quality of life into a directive clinical conclusion may be difficult. It should be noted that symptoms and quality of life are two separate clinical endpoints. Moreover, in most studies that report on both outcome measurements, symptoms and quality of life are only poorly correlated. 24, 27, 46 Even patients with highly symptomatic AF may report only mildly reduced quality of life overall whereas patients with silent AF (i.e. in the lowest quartile of symptom scores) report impaired well being compared with control patients in sinus rhythm. 21 Figure 2 illustrates a model of potential overlap between symptoms and quality of life in patients with AF.
Future of quality of life assessment in patients with atrial fibrillation
To date there is no consensus as to which instruments should be used to measure quality of life in patients with AF. Because of increasing data for comparison with other diseases, the SF-36 is now most commonly chosen to assess quality of life in patients with AF. The SF-36 has been shown to yield similar scores even in patients with different language and cultural backgrounds. 47, 48 The advantage of this standardization may be counterbalanced by the broad and non-specific character of the assessment that is rather insensitive to the burdens of AF. Therefore, a combination with a specific symptom checklist may represent the preferred approach for clinical and epidemiological research. Regarding the above-mentioned limitations, it is important to differentiate clearly symptoms and health status from quality of life. 49 Therefore, reasons for the use of a specific instrument and the expected endpoints should be clearly stated to avoid misinterpretation of the findings. Trials that are likely to impact on clinical practice must assess treatment effects on a clearly measured outcome that is most relevant to the well being of patients. 50 Ongoing studies will help to find appropriate treatments and will increase our understanding of the best outcome measures in AF. 
